Myopic Choroidal Neovascularization Clinical Trial
Official title:
Effect of Intravitreal Ranibizumab Injection on Aqueous Humor Concentrations of Vascular Endothelial Growth Factor and Pigment Epithelium-derived Factor in Patients With Myopic Choroidal Neovascularization.
This was a prospective, case-control study investigating aqueous levels of VEGF and PEDF in eyes with mCNV treated with IVB.
n/a
Observational Model: Case Control, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04524910 -
A Study to Learn More About How Drug Aflibercept Works in Canadian Patients With Reduced Vision Caused by New Blood Vessels Growing in the Eye (Myopic Choroidal Neovascularization or mCNV)
|
||
Active, not recruiting |
NCT01246089 -
Ranibizumab for Myopic Neovascularization
|
Phase 4 | |
Completed |
NCT00797992 -
Bevacizumab Intravitreal for Myopic Choroidal Neovascularization
|
Phase 4 |